Creative Medical Technology Holdings, Inc. (CELZ) stock
CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48−0.04 (-8.36%)
Close on Nov 17, 2026Market cap $3.14MP/E –Yield –
Creative Medical Technology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Creative Medical Technology's operating income for the twelve months ending Jun 30, 2026 was -$6.24M. For fiscal 2025 it was -$6.14M. The highest annual figure on record is -$14.29K in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.14M | – |
| FY2024 | Dec 31, 2024 | -$5.74M | – |
| FY2023 | Dec 31, 2023 | -$5.62M | – |
| FY2022 | Dec 31, 2022 | -$10.24M | – |
| FY2021 | Dec 31, 2021 | -$3.13M | – |
| FY2020 | Dec 31, 2020 | -$1.11M | – |
| FY2019 | Dec 31, 2019 | -$1.13M | – |
| FY2018 | Dec 31, 2018 | -$1.11M | – |
| FY2017 | Dec 31, 2017 | -$1.18M | – |
| FY2016 | Dec 31, 2016 | -$759.67K | – |
| FY2015 | Dec 31, 2015 | -$20.83K | – |
| FY2014 | Dec 31, 2014 | -$19.43K | – |
| FY2013 | Dec 31, 2013 | -$20.12K | – |
| FY2012 | Dec 31, 2012 | -$20.10K | – |
| FY2011 | Dec 31, 2011 | -$19.83K | – |
| FY2010 | Dec 31, 2010 | -$14.29K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.46M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.95M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.26M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.89M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$833.44K | – |
| Q2 FY2021 | Jun 30, 2021 | -$515.84K | – |
| Q1 FY2021 | Mar 31, 2021 | -$303.94K | – |
| Q4 FY2020 | Dec 31, 2020 | -$323.06K | – |
| Q3 FY2020 | Sep 30, 2020 | -$242.47K | – |
| Q2 FY2020 | Jun 30, 2020 | -$214.26K | – |
| Q1 FY2020 | Mar 31, 2020 | -$335.04K | – |
| Q4 FY2019 | Dec 31, 2019 | -$330.59K | – |
| Q3 FY2019 | Sep 30, 2019 | -$273.42K | – |
| Q2 FY2019 | Jun 30, 2019 | -$275.46K | – |
| Q1 FY2019 | Mar 31, 2019 | -$250.70K | – |
| Q4 FY2018 | Dec 31, 2018 | -$320.34K | – |
| Q3 FY2018 | Sep 30, 2018 | -$274.84K | – |
| Q2 FY2018 | Jun 30, 2018 | -$314.83K | – |
| Q1 FY2018 | Mar 31, 2018 | -$204.22K | – |
| Q4 FY2017 | Dec 31, 2017 | -$245.97K | – |
| Q3 FY2017 | Sep 30, 2017 | -$295.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$395.99K | – |
| Q1 FY2017 | Mar 31, 2017 | -$240.85K | – |
| Q4 FY2016 | Dec 31, 2016 | -$191.91K | – |
| Q3 FY2016 | Sep 30, 2016 | -$212.54K | – |
See a number that looks wrong?